Retrospective study of alectinib on long-term prognosis in poor performance status patients with ALK positive, advanced/recurrent NSCLC

Retrospective study of alectinib on long-term prognosis in poor performance status patients with ALK positive, advanced/recurrent NSCLC - LOGIK1401-B

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000035853

Enrollment

Registered

2019-02-12

Start date

2018-08-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small Cell Lung Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) 15 sites with participation to LOGIK1401 where patients were enrolled in LOGIK1401 2) Institutions approved by institutional ethics committee on this observational study.

Exclusion criteria

Exclusion criteria: Nothing particular

Design outcomes

Primary

Measure	Time frame
Progression free survival (PFS) Overall survival (OS) One-year overall survival Two-year overall survival Presence or absence of progression Pattern of progression (Presence or absence of progression of brain metastasis) Post-treatment: 2nd treatment after the failure of alectinib treatment	—

Countries

Japan

Contacts

Public ContactEiji Iwama

Kyushu University Hospital Research Institute for Disease of the Chest

iwama@kokyu.med.kyushu-u.ac.jp092-642-5378

Outcome results